Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke
PREVENTION AVC
1 other identifier
observational
18
1 country
1
Brief Summary
Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world. In France, they are the leading cause of death in women and the third cause in men. Sequelae and disabilities also represent a significant financial cost for health insurance. The early management of the treatment improves the patient's vital and functional prognosis. The ability of the patient to identify the signs of stroke requiring urgent consultation and proper orientation are therefore crucial for further management. The most common signs that patients must recognize are muscle weakness or sudden paralysis of an arm, leg or half of the body, asymmetry of the face, tingling, numbness of a hemi-body, speech or understanding, loss of vision of an eye or hemifield, disorder of the coordination of a hemi-body. The variety of clinical pictures complicates primary prevention. In this context, a 2010-2014 National Stroke Action Plan was undertaken with the aim, among other things, of developing information to prevent stroke and to limit its sequelae. In this plan, the attending physician must improve prevention in high-risk patients and be a link between the city and the hospital for follow-up. Several questions arise:
- Are patients who are regularly followed by a general practitioner better educated on the signs of stroke / TIA and thus more able to give an appropriate warning?
- What is the profile of patients who have not been affected by the different modes of primary prevention?
- What are the effective means of information and those desired
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 24, 2019
CompletedFirst Posted
Study publicly available on registry
June 5, 2019
CompletedStudy Start
First participant enrolled
June 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 5, 2019
CompletedDecember 6, 2019
December 1, 2019
2 months
May 24, 2019
December 5, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Time until patient's care in the hospital after stroke's symptoms
The delay between the observation of signs of stroke and specialized neurovascular management at the hospital will be measured. This measures the impact of physician's prevention on the management of stroke.
Day 1
Secondary Outcomes (1)
Study the different effective means of primary prevention
Day 1
Study Arms (1)
Patients with stroke
In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
Interventions
In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
Eligibility Criteria
Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
You may qualify if:
- Patient whose age is ≥ 18 years
- Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
- Francophone patient
You may not qualify if:
- Patient with previously labeled cognitive impairment
- Patient under tutorship or curatorship
- Patient deprived of liberty
- Patient unable to answer the questionnaire
- Patient opposing participation in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Groupe Hospitalier Paris Saint-Joseph
Paris, 75014, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marie BRUANDET, MD
Fondation Hôpital Saint-Joseph
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 24, 2019
First Posted
June 5, 2019
Study Start
June 7, 2019
Primary Completion
July 29, 2019
Study Completion
December 5, 2019
Last Updated
December 6, 2019
Record last verified: 2019-12